Neurocrine Biosciences (NBIX) Liabilities and Shareholders Equity (2010 - 2026)

Neurocrine Biosciences has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $5.4 billion in Q2 2026.

• Liabilities and Shareholders Equity for Q2 2026 came in at $5.4 billion, up 37.77% year-over-year; the trailing twelve-month figure through Jun 2026 was $19.2 billion (up 29.2% YoY), and the FY2025 annual result was $4.6 billion, up 24.55% from the prior year.
• Liabilities and Shareholders Equity grew to $5.4 billion in Q2 2026, from $4.9 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $5.4 billion in Q2 2026 and troughed at $2.0 billion in Q2 2022.
• A 5-year average of $3.4 billion and a median of $3.4 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The widest annual swing landed in 2022, when Liabilities and Shareholders Equity rose 2.52%; it then soared 47.15% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $2.4 billion in 2022, then soared by 37.27% to $3.3 billion in 2023, then gained by 14.37% to $3.7 billion in 2024, then increased by 24.55% to $4.6 billion in 2025, then climbed by 15.71% to $5.4 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $5.4 billion in Q2 2026, $4.9 billion in Q1 2026, and $4.6 billion in Q4 2025.